BTIG Research Predicts Over 118% Rally for These 3 Stocks

InvestorPlace04-16

As the technology sector was a primary driver of the stock market, it may have run its course with new opportunities opening up. Theravance Bipopharma (TBPH): The biotech is seeing good results on a ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2427882258?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-16 02:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2427882258","market":"us","top_or_hot":-1,"title":"BTIG Research Predicts Over 118% Rally for These 3 Stocks","media":"InvestorPlace","content":"<div>\n<p>As the technology sector was a primary driver of the stock market, it may have run its course with new opportunities opening up.\nTheravance Bipopharma (TBPH): The biotech is seeing good results on a ...</p>\n\n<a href=\"https://investorplace.com/2024/04/btig-research-predicts-over-118-rally-for-these-3-stocks/\">Source Link</a>\n\n</div>\n","source":"investorplace_stock_picks","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BTIG Research Predicts Over 118% Rally for These 3 Stocks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBTIG Research Predicts Over 118% Rally for These 3 Stocks\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-16 02:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2024/04/btig-research-predicts-over-118-rally-for-these-3-stocks/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As the technology sector was a primary driver of the stock market, it may have run its course with new opportunities opening up.\nTheravance Bipopharma (TBPH): The biotech is seeing good results on a ...</p>\n\n<a href=\"https://investorplace.com/2024/04/btig-research-predicts-over-118-rally-for-these-3-stocks/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BTDR","symbol_name":"Bitdeer Technologies Group","start_time":0,"source_url":"https://investorplace.com/2024/04/btig-research-predicts-over-118-rally-for-these-3-stocks/","article_id":"2427882258","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2427882258","pubTimestamp":1713205193,"sourceInfo":{"source_id":"investorplace_stock_picks","name":"InvestorPlace stock picks"},"weMediaInfo":null,"summary":"As the technology sector was a primary driver of the stock market, it may have run its course with new opportunities opening up.Theravance Bipopharma : The biotech is seeing good results on a therapy for falling blood pressure in Parkinson’s patients.AnaptysBio : Another biotech, ANAB is looking to treat autoimmune issues, though its outlook is a bit dicier.Bitdeer Technologies : This bitcoin miner could quadruple capacity at lower energy costs the way it is going.However, analysts at the wealth management arm of Goldman Sachs think the tech sector may have run its course. They say it is time to start looking elsewhere. Investors would be better off taking the profits they’ve made in tech and deploying them in other sectors. The investment firm is leaning into energy and Japanese stocks.Theravance is receiving revenue from Viatris , which sells the biopharma’s Yupelri. This is a treatment for patients with chronic obstructive pulmonary disease . Theravance receives 35% of all sales, or","collect":0,"end_time":0,"defaultTopTitle":"investorplace.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BTDR":"Bitdeer Technologies Group","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","QID":"纳指两倍做空ETF","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","VTRS":"Viatris Inc.","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","TBPH":"Theravance Biopharma Inc.","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0971096721.USD":"富达环球金融服务 A","ANAB":"Anaptysbio Inc","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","BRK.B":"伯克希尔B","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU0149725797.USD":"汇丰美国股市经济规模基金","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU0882574139.USD":"富达环球消费行业基金A ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","PSQ":"纳指反向ETF","QLD":"纳指两倍做多ETF","QQQ":"纳指100ETF","LU0742534661.SGD":"Fidelity America A-SGD (hedged)","TQQQ":"纳指三倍做多ETF","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","IE00B775SV38.USD":"NEUBERGER BERMAN US MULTICAP OPPORTUNITIES \"A\" (USD) ACC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","SMCI":"超微电脑","LLY":"礼来","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU0048573561.USD":"FIDELITY AMERICA \"A\" (USD) INC","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc",".IXIC":"NASDAQ Composite","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","SQQQ":"纳指三倍做空ETF","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","BK4534":"瑞士信贷持仓"},"translate_title":"BTIG Research预测这三只股票将上涨118%以上","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANAB":1,"VTRS":1,"TBPH":1,"SMCI":1,"LLY":1,"BTDR":1,".IXIC":0.9,"BRK.B":0.67,"PSQ":0.6,"QID":0.6,"QLD":0.6,"QQQ":0.6,"SQQQ":0.6,"TQQQ":0.6,"MNQmain":0.6,"NQmain":0.6},"content_text":"As the technology sector was a primary driver of the stock market, it may have run its course with new opportunities opening up.\nTheravance Bipopharma (TBPH): The biotech is seeing good results on a therapy for falling blood pressure in Parkinson’s patients.\nAnaptysBio (ANAB): Another biotech, ANAB is looking to treat autoimmune issues, though its outlook is a bit dicier.\nBitdeer Technologies (BTDR): This bitcoin miner could quadruple capacity at lower energy costs the way it is going.\n \n\n\n\n \n\nSource: Overearth / Shutterstock\n\n\n\nThe stock market may have pulled back a bit from the all-time high reached late last month but the S&P 500 remains 7.4% higher in 2024. Technology stocks continue to be top performers with Super Micro Computer (NASDAQ:SMCI) leading the way with a 216% gain so far.\nHowever, analysts at the wealth management arm of Goldman Sachs think the tech sector may have run its course. They say it is time to start looking elsewhere. Investors would be better off taking the profits they’ve made in tech and deploying them in other sectors. The investment firm is leaning into energy and Japanese stocks.\nThat follows Warren Buffett’s thinking. The Oracle of Omaha has been busily buying energy stocks for Berkshire Hathaway (NYSE:BRK-A)(NYSE:BRK-B). And, in his annual shareholder letter he called out the CEOs of the five Japanese banks he owns as models their American counterparts ought to follow.\nAnalysts at global financial services firm BTIG Research appear to agree but have different ideas on where to invest. Biotechnology dominates the coverage they’ve recently initiated. Below are the stock predictions of three companies they forecast have tremendous upside potential. The stocks are seen growing 118% or more. Let’s see why.\nTheravance Biopharma (TBPH)\nSource: Sisacorn / Shutterstock.comBTIG analyst Julian Harrison initiated coverage last week on Theravance Biopharma (NASDAQ: TBPH) with a buy rating and a price target of $21 per share. The one-year price target on the biopharmaceutical stock implies growth potential of more than 118.% over where TBPH stock closed trading on Friday. \nHis thesis is phase 3 data for Theravance’s investigational drug ampreloxetine is due in 2025 and should be positive. The therapy treats neurogenic orthostatic hypotension, a drop in blood pressure particularly as experienced by Parkinson’s patients.\nHarrison finds Theravance in excellent financial shape ahead of the report. The biopharma has no long-term debt (it does have $45 million in long-term operating leases, though), has cut operating expenses by 60% over the past four years and has been buying back stock at a health clip. He notes management anticipates minimal cash burn ahead of the data.\nTheravance is receiving revenue from Viatris (NASDAQ:VTRS), which sells the biopharma’s Yupelri. This is a treatment for patients with chronic obstructive pulmonary disease (COPD). Theravance receives 35% of all sales, or $57.2 million in 2023. The biopharma will register to sell the drug in China beginning in mid-2024. Theravance Biopharma stock could take off this year if approval is granted.\nAnaptysBio (ANAB)\nSource: Pavel Kapysh / Shutterstock.comAnother biotech BTIG sees a bright future for is AnaptysBio (NASDAQ:ANAB). The company seeks to treat various autoimmune diseases through checkpoint agonism, or creating a physiological response when a therapy is combined with a receptor. AnaptysBio points to conditions such as ulcerative colitis where, despite existing treatments, there is still significant unmet need.\nBTIG notes it’s not a clearcut path to growth for AnaptysBio. The analyst says safety concerns were previously raised when checkpoint agonism was used in cancer treatment, but they may be overstated. As a result, BTIG is watching the progress Eli Lilly (NYSE:LLY) is making using agonism with peresolimab, a therapy for rheumatoid arthritis. A positive outcome could boost AnaptysBio stock by 75% or more. A negative outcome could result in a 20% to 40% decline. The firm, though, is feeling upbeat about Lilly’s prospects.\nBTIG initiated coverage of AnaptysBio with a buy rating and a $55 per share price target, some 142% above Friday’s close. Also, Wells Fargo weighed in on the biotech last week and set a $56 per share price target.\nBitdeer Technologies (BTDR)\nSource: Michal Bednarek / ShutterstockBTIG isn’t completely willing to abandon the technology sector as it initiated coverage on bitcoin miner Bitdeer Technologies (NASDAQ:BTDR). Analyst Gregory Lewis issued a buy rating with a $15 per share price target, 148% above its Friday close. He points to  Bitdeer’s mining operations as well as its diversification. Additionally, it has a substantial self-mining hash rate and hosting capabilities. As of Feb. 29, Bitdeer had a proprietary hash rate of 8.4 exahashes per second (EH/s).\nHowever, Lewis’ buy rating is based on Bitdeer’s strategic investments in equipment technology as well as having an advantageous power infrastructure. The analyst notes the miner wants to quadruple its self-mining capacity to around 30 EH/s. It could achieve that by successfully developing 1,075 megawatts (MW) of power infrastructure.\nInvestorPlace contributor Alex Sirois maintains Bitdeer Technologies is the lowest all-in cost Bitcoin miner by a long shot. Although it had a disappointing earnings report, the bitcoin miner still grew revenue and narrowed losses. That suggests the faith Wall Street is putting in Bitdeer Technologies stock may not be misplaced.\nOn the date of publication, Rich Duprey did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.\nRich Duprey has written about stocks and investing for the past 20 years. His articles have appeared on Nasdaq.com, The Motley Fool, and Yahoo! Finance, and he has been referenced by U.S. and international publications, including MarketWatch, Financial Times, Forbes, Fast Company, USA Today, Milwaukee Journal Sentinel, Cheddar News, The Boston Globe, L’Express, and numerous other news outlets.Biotech, Financial, Fintech, HealthcareGrowth Stocks\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSubmit\n\n\n\n\n\n\n\nArticle printed from InvestorPlace Media, https://investorplace.com/2024/04/btig-research-predicts-over-118-rally-for-these-3-stocks/.\n©2024 InvestorPlace Media, LLC","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2427882258"}